Table 1. Emerging adverse prognostic... | American Society of Hematology

Table 1.

Emerging adverse prognostic markers in bispecific antibody therapy

Poor prognostic marker	Cohort	Bispecific antibody analyzed	Number	Timepoint assessed	Outcome measure affected
ECOG >0	Retrospective⁵	CD20/CD3	N = 143	≥1 prior line of therapy	Inferior OS
Male sex	Prospective¹^,²	• Glofitamab • Epcoritamab	• N = 154 • N = 157	>1 prior line of therapy	Lower CR rate
Chemotherapy refractoriness	Prospective¹ + Retrospective⁵	• Glofitamab • CD20/CD3	• N = 154 • N = 104	≥1 prior line of therapy	• Lower CR rate • Inferior PFS/OS
High inflammatory markers: IL-6, IL-8, CRP	Prospective⁸	Glofitamab	N = 119	≥1 prior line of therapy	Lower CR rate
Increased LDH	Retrospective⁵	CD20/CD3	N = 104	≥1 prior line of therapy	Inferior PFS/OS
TMTV ≥ median	Retrospective¹²	Glofitamab	N = 144	>1 prior line of therapy	Inferior PFS
Tumor: <10% CD20 expression	Retrospective¹³	Mosunetuzumab	N = 161	≥2 prior therapies	Reduced ORR
Tumor: molecular aberrations MYC, TP53, RHOA, CD274, GNAI2	Retrospective⁸^,¹⁴	• Glofitamab • CD20/CD3	N = 33 N = 36	>1 prior line of therapy	• Reduced ORR • Inferior PFS/OS
TME: increased “exhausted” CD8 T cells	Retrospective¹¹	CD20/CD3	N = 7	>1 prior line of therapy	Higher relapse rate

Poor prognostic marker	Cohort	Bispecific antibody analyzed	Number	Timepoint assessed	Outcome measure affected
ECOG >0	Retrospective⁵	CD20/CD3	N = 143	≥1 prior line of therapy	Inferior OS
Male sex	Prospective¹^,²	• Glofitamab • Epcoritamab	• N = 154 • N = 157	>1 prior line of therapy	Lower CR rate
Chemotherapy refractoriness	Prospective¹ + Retrospective⁵	• Glofitamab • CD20/CD3	• N = 154 • N = 104	≥1 prior line of therapy	• Lower CR rate • Inferior PFS/OS
High inflammatory markers: IL-6, IL-8, CRP	Prospective⁸	Glofitamab	N = 119	≥1 prior line of therapy	Lower CR rate
Increased LDH	Retrospective⁵	CD20/CD3	N = 104	≥1 prior line of therapy	Inferior PFS/OS
TMTV ≥ median	Retrospective¹²	Glofitamab	N = 144	>1 prior line of therapy	Inferior PFS
Tumor: <10% CD20 expression	Retrospective¹³	Mosunetuzumab	N = 161	≥2 prior therapies	Reduced ORR
Tumor: molecular aberrations MYC, TP53, RHOA, CD274, GNAI2	Retrospective⁸^,¹⁴	• Glofitamab • CD20/CD3	N = 33 N = 36	>1 prior line of therapy	• Reduced ORR • Inferior PFS/OS
TME: increased “exhausted” CD8 T cells	Retrospective¹¹	CD20/CD3	N = 7	>1 prior line of therapy	Higher relapse rate

CR, complete response; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; IL, interleukin; LDH, lactate dehydrogenase; N, number; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TME, tumor microenvironment; TMTV, total metabolic tumor volume.

[ViewLarge]

This Feature Is Available To Subscribers Only